Published in Cancer Res on May 20, 2011
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology (2014) 2.30
Tumor promotion via injury- and death-induced inflammation. Immunity (2011) 1.81
HMGB1 in cancer: good, bad, or both? Clin Cancer Res (2013) 1.79
HMGB1 in health and disease. Mol Aspects Med (2014) 1.67
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2014) 1.49
Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ (2013) 1.39
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 1.31
Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. Oncoimmunology (2014) 1.30
Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol (2016) 1.26
Enlightening the impact of immunogenic cell death in photodynamic cancer therapy. EMBO J (2012) 1.14
Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ (2013) 1.13
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. Front Immunol (2015) 1.12
Many faces of DAMPs in cancer therapy. Cell Death Dis (2013) 1.11
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 1.07
Clinical opportunities in combining immunotherapy with radiation therapy. Front Oncol (2012) 1.04
Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology (2015) 1.02
Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy. Curr Mol Med (2012) 0.99
Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner. Cell Death Dis (2015) 0.99
Combinatorial strategies for the induction of immunogenic cell death. Front Immunol (2015) 0.98
Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer. Int J Cancer (2013) 0.98
Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. J Virol (2014) 0.95
Immunogenic tumor cell death induced by chemoradiotherapy: molecular mechanisms and a clinical translation. Cell Death Dis (2013) 0.93
Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors. Nanomedicine (2014) 0.92
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget (2015) 0.92
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. Vaccines (Basel) (2015) 0.91
Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology (2014) 0.90
Mechanisms of Translocation of ER Chaperones to the Cell Surface and Immunomodulatory Roles in Cancer and Autoimmunity. Front Oncol (2015) 0.90
Rose Bengal acetate photodynamic therapy (RBAc-PDT) induces exposure and release of Damage-Associated Molecular Patterns (DAMPs) in human HeLa cells. PLoS One (2014) 0.90
Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol (2015) 0.89
Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood (2016) 0.86
Capsaicin as an inducer of damage-associated molecular patterns (DAMPs) of immunogenic cell death (ICD) in human bladder cancer cells. Cell Stress Chaperones (2013) 0.85
Local tumour hyperthermia as immunotherapy for metastatic cancer. Int J Hyperthermia (2014) 0.83
Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. Oncotarget (2015) 0.83
Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation. Cell Death Differ (2016) 0.82
Combined Tumor Cell-Based Vaccination and Interleukin-12 Gene Therapy Polarizes the Tumor Microenvironment in Mice. Arch Immunol Ther Exp (Warsz) (2015) 0.82
Cancer cell response to anthracyclines effects: mysteries of the hidden proteins associated with these drugs. Int J Mol Sci (2012) 0.81
Tumor infiltrating CD8(+) T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma. Oncoimmunology (2015) 0.81
Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis. Oncoimmunology (2015) 0.80
Toll-like receptors in prostate infection and cancer between bench and bedside. J Cell Mol Med (2013) 0.80
Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum Vaccin Immunother (2014) 0.80
Activated amelogenin Y-linked (AMELY) regulation and angiogenesis in human hepatocellular carcinoma by biocomputation. Oncol Lett (2013) 0.80
Immunogenic Cell Death Induced by Ginsenoside Rg3: Significance in Dendritic Cell-based Anti-tumor Immunotherapy. Immune Netw (2016) 0.79
Photodynamic therapy-mediated cancer vaccination enhances stem-like phenotype and immune escape, which can be blocked by thrombospondin-1 signaling through CD47 receptor protein. J Biol Chem (2015) 0.78
Editorial: Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Reality. Front Immunol (2016) 0.78
Dendritic cells combined with doxorubicin induces immunogenic cell death and exhibits antitumor effects for osteosarcoma. Oncol Lett (2016) 0.77
Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate. Oncoimmunology (2016) 0.76
Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death. Oncoimmunology (2016) 0.76
Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death. J Immunother Cancer (2017) 0.75
Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death. Oncoimmunology (2016) 0.75
Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy. Cancer Microenviron (2013) 0.75
Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells. Oncoimmunology (2017) 0.75
Immunogenicity of mammary tumor cells can be induced by shikonin via direct binding-interference with hnRNPA1. Oncotarget (2016) 0.75
Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. Oncoimmunology (2015) 0.75
Induction of immunogenic cell death of tumors by newly synthesized heterocyclic quinone derivative. PLoS One (2017) 0.75
Autophagy, autophagy-associated adaptive immune responses and its role in hematologic malignancies. Oncotarget (2016) 0.75
The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy. Vaccines (Basel) (2016) 0.75
Cytokines in immunogenic cell death: Applications for cancer immunotherapy. Cytokine (2017) 0.75
Trial watch: Dendritic cell-based anticancer immunotherapy. Oncoimmunology (2017) 0.75
The novel immunomodulator IMMUNEPOTENT CRP combined with chemotherapy agent increased the rate of immunogenic cell death and prevented melanoma growth. Oncol Lett (2017) 0.75
Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? Target Oncol (2017) 0.75
Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. N Engl J Med (2015) 3.37
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Autoimmune lymphoproliferative syndrome with somatic Fas mutations. N Engl J Med (2004) 2.25
Predicting term birth weight using ultrasound and maternal characteristics. Eur J Obstet Gynecol Reprod Biol (2006) 2.02
Less radical surgery than radical hysterectomy in early stage cervical cancer: a pilot study. Gynecol Oncol (2009) 1.70
Influence of oral vitamin E therapy on micro-inflammation and cardiovascular disease markers in chronic hemodialysis patients. Ren Fail (2006) 1.43
Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clin Immunol (2006) 1.23
Gliadin fragments induce phenotypic and functional maturation of human dendritic cells. J Immunol (2005) 1.16
Presentation, management and outcome of 32 patients with pregnancy-associated breast cancer: a matched controlled study. Breast J (2009) 1.05
Primary Sjögren syndrome in the paediatric age: a multicentre survey. Eur J Pediatr (2003) 1.04
Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin Immunol (2009) 1.02
Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia. Blood (2006) 1.00
Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation. Int J Cancer (2010) 0.96
Maturation state of dendritic cells during the extracorporeal photopheresis and its relevance for the treatment of chronic graft-versus-host disease. Transfusion (2006) 0.96
Kinetics of Toll-like receptor-4 splice variants expression in lipopolysaccharide-stimulated antigen presenting cells of healthy donors and patients with cystic fibrosis. Microbes Infect (2007) 0.94
High hydrostatic pressure induces immunogenic cell death in human tumor cells. Int J Cancer (2014) 0.94
Silica and asbestos exposure in ANCA-associated vasculitis with pulmonary involvement. Ren Fail (2005) 0.94
FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer. Clin Immunol (2009) 0.92
Current status of sentinel lymph node mapping in the management of cervical cancer. Expert Rev Anticancer Ther (2013) 0.92
Human papillomavirus (HPV) profiles of vulvar lesions: possible implications for the classification of vulvar squamous cell carcinoma precursors and for the efficacy of prophylactic HPV vaccination. Am J Surg Pathol (2007) 0.91
The role of neoadjuvant chemotherapy and surgery in cervical cancer. Int J Gynecol Cancer (2010) 0.90
Differential cytokine profile in children with cystic fibrosis. Clin Immunol (2005) 0.89
A prospective study of sentinel lymph node status and parametrial involvement in patients with small tumour volume cervical cancer. Gynecol Oncol (2008) 0.88
Human papillomavirus genotype distribution in Czech women and men with diseases etiologically linked to HPV. PLoS One (2011) 0.87
Review of neoadjuvant chemotherapy and trachelectomy: which cervical cancer patients would be suitable for neoadjuvant chemotherapy followed by fertility-sparing surgery? Curr Oncol Rep (2015) 0.85
Kinetics of dendritic cells reconstitution and costimulatory molecules expression after myeloablative allogeneic haematopoetic stem cell transplantation: implications for the development of acute graft-versus host disease. Clin Immunol (2008) 0.84
Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scand (2010) 0.83
Unrelated partially matched lymphocyte infusions in a patient with complete DiGeorge/CHARGE syndrome. Pediatr Transplant (2007) 0.83
A prospective study in detection of lower-limb lymphedema and evaluation of quality of life after vulvar cancer surgery. Int J Gynecol Cancer (2012) 0.83
Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol (2008) 0.82
Maturation of dendritic cells by bacterial immunomodulators. Vaccine (2004) 0.82
Sentinel lymph node biopsy in patients with gynecologic cancers Expert panel statement from the International Sentinel Node Society Meeting, February 21, 2008. Gynecol Oncol (2009) 0.82
Current status of sentinel lymph node mapping in the management of endometrial cancer. Expert Rev Anticancer Ther (2013) 0.81
Generation of functional dendritic cells for potential use in the treatment of acute lymphoblastic leukemia. Cancer Immunol Immunother (2002) 0.78
Lymphatic mapping in endometrial cancer: comparison of hysteroscopic and subserosal injection and the distribution of sentinel lymph nodes. Int J Gynecol Cancer (2009) 0.78
In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients. Clin Immunol (2006) 0.77
A prospective study of postoperative lymphedema after surgery for cervical cancer. Int J Gynecol Cancer (2010) 0.77
A prospective study in the evaluation of quality of life after vulvar cancer surgery. Int J Gynecol Cancer (2015) 0.77
ESGO statement on cervical cancer vaccination. Int J Gynecol Cancer (2007) 0.77
Extracorporeal photochemotherapy (ECP) in treatment of patients with c-GVHD and CTCL. Transfus Apher Sci (2007) 0.76
High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer. Gynecol Oncol (2012) 0.76
The association of taxane resistance genes with the clinical course of ovarian carcinoma. Genomics (2013) 0.76
Detection of Helicobacter pylori in oropharyngeal lymphatic tissue with real-time PCR and assessment of its carcinogenic potential. Eur Arch Otorhinolaryngol (2013) 0.75
Methods of dendritic cell preparation for acute lymphoblastic leukemia immunotherapy in children. Med Oncol (2005) 0.75
Immunology in the heart of the High Tatra mountains. Eur J Immunol (2011) 0.75
European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer. Int J Gynecol Cancer (2017) 0.75
p16(INK4a) immunoprofiles of squamous lesions of the uterine cervix-implications for the reclassification of atypical immature squamous metaplasia. Pathol Oncol Res (2013) 0.75
European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer. Int J Gynecol Cancer (2017) 0.75
Influence of parenteral iron therapy and oral vitamin E supplementation on neutrophil respiratory burst in chronic hemodialysis patients. Ren Fail (2005) 0.75